TICKERNERD
Menu
DYNDYNHealthcare · Biotechnology

DYN Stock Forecast: Dyne Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$19
+1.70% on the day

The 17 Wall Street analysts covering Dyne Therapeutics, Inc. hold a median 12-month price target of $37 — +99.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 14 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$3.4B
Ticker Nerd rank
23 / 100
Median analyst target
$37
Analysts covering
17
Revenue$0.0
Operating income−$181.7M
Net income−$178.6M
Free cash flow−$131.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−23.7%
1M
−27.9%
YTD
−5.3%
1Y
+40.8%
From 52W high
−30.8%
From 52W low
+49.7%
$12
$27
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DYN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Dyne Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Sept 2026
23 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
78
Growth
52
Value
52
Quality
50
Accruals
35
Size
28
Volatility
28
Revisions
27
Issuance
8

Momentum (78): The shares have been drifting up relative to others.

Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DYN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DYN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26DYNHigh $50Median $37Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says17 analysts
16 Buy0 Hold1 Sell
Low $10Median $37High $50

The green dot is the last close — the median target sits +99.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
9 Sept 2026BairdMaintainsOutperform$30 → $26
9 Sept 2026JP MorganDowngradeUnderweight$17 → $10
9 Sept 2026Morgan StanleyMaintainsOverweight$45 → $36
9 Sept 2026RBC CapitalMaintainsOutperform$35 → $30
31 July 2026Morgan StanleyMaintainsOverweight—
31 July 2026Morgan StanleyMaintainsOverweight$47 → $45
30 July 2026RBC CapitalMaintainsOutperform$30 → $35
30 July 2026RBC CapitalMaintainsOutperform—
23 July 2026Cantor FitzgeraldInitiatesOverweight—
23 July 2026Cantor FitzgeraldInitiatesOverweight—
26 June 2026TD CowenInitiatesBuy—
26 June 2026TD CowenInitiatesBuy—
15 May 2026Evercore ISI GroupMaintainsOutperform—
13 May 2026BernsteinMaintainsMarket Perform—
9 Mar 2026Chardan CapitalMaintainsBuy—
3 Mar 2026Chardan CapitalMaintainsBuy—
3 Mar 2026HC Wainwright & Co.MaintainsBuy—
3 Mar 2026Morgan StanleyMaintainsOverweight—
20 Jan 2026JP MorganMaintainsNeutral—
15 Dec 2025Evercore ISI GroupMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DYN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

DYN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, Dyne Therapeutics, Inc. returned +40.8% against +17.0% for the S&P 500, dividends included.

DYN vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200220Oct 25Jan 26Apr 26Jul 26DYNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DYN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
11
Fundamentals

Dyne Therapeutics, Inc. (DYN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.3×

Cheaper than 90% of US stocks

Price / sales
—
Price / book
4.3×

Cheaper than 24% of US stocks

EV / EBITDA
−5.1×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−81.6%

Higher than 16% of US stocks

Return on assets
−39.0%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Dyne Therapeutics, Inc. (DYN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Dyne Therapeutics, Inc. has a market value of $3.4B and an enterprise value of $2.7B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$519.4M.

  • Diluted earnings per share, trailing twelve months: $−3.33.

  • Free cash flow in the twelve months to 30 June 2026: −$499.2M.

  • Shares outstanding: 165.7M.

  • Trailing P/E: −5.3×; forward P/E: −5.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Dyne Therapeutics, Inc. employs 289 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Sept 2026

Data provided by Twelve Data

Peers

DYN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DYNDyne Therapeutics, Inc.$3.4B
23
TARSTarsus Pharmaceuticals, Inc.$3.4B
83
DNLIDenali Therapeutics, Inc.$3.3B
58
IDYAIDEAYA Biosciences, Inc.$3.6B
80
ABCLAbCellera Biologics, Inc.$3.6B
71
VKTXViking Therapeutics, Inc.$3.6B
28
QUREUniQure NV$3.1B
60

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Dyne Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DYN news & analysis

Dyne Therapeutics, Inc. (DYN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 14 Sept 2026neutral

Dyne Therapeutics presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation published on Seeking Alpha. The presentation covered the company's updates at the industry conference.

Why it matters — A DYN watcher would care because the conference presentation offers investors insight into the company's positioning and updates as communicated by management.

Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class

Seeking Alpha · 9 Sept 2026positive

Dyne Therapeutics' stock fell 16% after Novartis' DM1 (HARBOR) trial failure raised platform-wide clinical risk concerns about RNA-targeting therapies. The item keeps a Buy rating on DYN but notes that its lead asset, z-rostudirsen, now faces regulatory and confirmatory risks with more uncertain long-term value due to functional outcome concerns.

Why it matters — A DYN watcher would care because the Novartis trial failure casts doubt on the class-wide RNA-targeting approach, directly affecting the prospects and perceived risk of DYN's own DM1 and DMD programs.

Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling

Benzinga · 8 Sept 2026negative

Dyne Therapeutics shares traded lower on Tuesday following Novartis's release of data from the global Phase 3 HARBOR study of del-desiran for myotonic dystrophy type 1 (DM1). The stock's decline was in reaction to the Novartis trial results.

Why it matters — Dyne Therapeutics is a DM1-focused company that competes with Novartis in the same therapeutic area, so the competitor's Phase 3 trial outcome is directly relevant to investors watching DYN.

Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers

Reuters · 8 Sept 2026negative

Shares of Dyne Therapeutics and Sarepta fell on Tuesday after Novartis' treatment for a muscle-wasting disorder failed in a trial. The setback fueled investor concerns about the prospects of similar therapies for this rare disease.

Why it matters — Dyne Therapeutics develops muscle disease therapies in the same space, so a major competitor's trial failure could raise investor uncertainty about the viability of similar approaches.

Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings

GlobeNewsWire · 8 Sept 2026positive

Dyne Therapeutics announced it will present additional one-year clinical data from the Phase 1/2 ACHIEVE trial of Z-Basivarsen (DYNE-101) for myotonic dystrophy type 1 at upcoming medical meetings. The presentation includes a pooled dose group from the multiple ascending dose portion of the trial compared against a matched natural history cohort.

Why it matters — DYN watchers would care because additional clinical data updates, particularly one-year results compared with a natural history cohort, could offer further insight into the drug candidate's potential for treating DM1.

FAQ

Frequently asked questions about DYN stock

What is the DYN stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Dyne Therapeutics, Inc. have a median 12-month price target of $37, with estimates ranging from $10 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DYN stock a buy right now?

Of the 17 analysts covering Dyne Therapeutics, Inc., 16 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Dyne Therapeutics, Inc. 23 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DYN?

As at 14 Sept 2026, Dyne Therapeutics, Inc. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (78 of 100).

Will DYN stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +99.8% from the last close, and Ticker Nerd's factor model ranks Dyne Therapeutics, Inc. 23 out of 100 as at 14 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DYN stock forecast for 2030?

No analyst covering Dyne Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DYN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $50 over the next 12 months.

How has DYN stock performed over the past year?

Dyne Therapeutics, Inc. returned +40.8% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Dyne Therapeutics, Inc. do?

Dyne Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for genetically driven neuromuscular diseases.

What is the latest news on DYN?

The most recent item we track (Seeking Alpha, 14 Sept 2026): "Dyne Therapeutics, Inc. (DYN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript". Dyne Therapeutics presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation published on Seeking Alpha. The presentation covered the company's updates at the industry conference.

Company

About Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for genetically driven neuromuscular diseases. Dyne Therapeutics advances a pipeline of investigational medicines designed to deliver treatment directly to muscle tissue and, in some programs, the central nervous system through its proprietary FORCE platform. Its current programs address conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease, along with other rare skeletal, cardiac, and metabolic muscle disorders. The company’s work centers on disease-modifying approaches aimed at the underlying genetic causes of these conditions, positioning it as a specialized player in rare disease drug development. Dyne Therapeutics is headquartered in Waltham, Massachusetts.

CEO Mr. John G. Cox M.B.A. · 289 employees · United States · https://www.dyne-tx.com